Faulding Profitable; New Drugs Introduced

8 September 1996

Generics manufacturer Faulding Inc of the USA, which was formerly Purepac, returned to profitability in the fourth quarter ended June 30, 1996, thanks to extra sales volume resulting from new product approvals, particularly for its anti-inflammatory drug diclofenac.

In the fourth quarter, sales amounted to $23.6 million, up 43.9%, and net profits were $666,000, compared with a loss of $603,000 a year earlier.

For the full year, the firm had a restated loss of $5 million on restated turnover of $75.8 million, compared with a restated loss of $1.6 million and turnover of $64.9 million. $4.1 million in pretax losses was included from an acqusition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight